Assertio Therapeutics (ASRT) AI Stock Analysis

• Market Cap: $69.79M
• Dividend Yield: N/A
• Average Volume (3M): 295.13K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.82
• Revenue Growth: 9.21%
• EPS Growth: 58.12%
• Country: US
• Employees: 58
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): 0.11
• Shares Outstanding: 96,239,624
• 10 Day Avg. Volume: 250,113
• 30 Day Avg. Volume: 295,133
• PEG Ratio: 0.04
• Price to Book (P/B): 0.69
• Price to Sales (P/S): 0.66
• P/FCF Ratio: 3.14
• Enterprise Value/Market Cap: 0.13
• Enterprise Value/Revenue: 0.07
• Enterprise Value/Gross Profit: 0.10
• Enterprise Value/Ebitda: 1.54
• 1Y Price Target: $3.00
• Price Target Upside: 284.62% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 3
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 49 Neutral
• Price Target: $0.50 ▼(-35.90% Downside)

Assertio Therapeutics faces significant financial challenges, with negative profitability and cash flow issues being the most impactful factors. While the earnings call provided some positive insights into sales growth and strategic advancements, the overall financial health and valuation concerns weigh heavily on the stock's attractiveness. Technical indicators also suggest a bearish outlook, further contributing to the low overall score.

Positive Factors

Rolvedon Sales Growth

The significant increase in Rolvedon sales demonstrates Assertio's ability to expand its market share and enhance revenue streams, supporting long-term growth.

Leadership Change

The appointment of a new CEO with a strong track record in specialty pharmaceuticals is expected to drive strategic growth and operational efficiency.

Cash Flow Improvement

The significant improvement in cash flow indicates enhanced financial health, providing more resources for investment and strategic initiatives.

Negative Factors

Declining Revenue

Declining revenues highlight challenges in maintaining market competitiveness and could impact long-term financial stability.

Indocin Sales Decline

The decline in Indocin sales due to generic competition poses a risk to Assertio's revenue base and market position in pain management.

Profitability Challenges

Ongoing profitability issues indicate structural challenges in cost management and pricing power, affecting long-term financial health.

Assertio Therapeutics Business Overview & Revenue Model

Company Description

Assertio Therapeutics, Inc. (ASRT) is a biopharmaceutical company focused on developing and commercializing innovative therapeutics for patients with pain and other neurological disorders. The company operates primarily in the pharmaceutical sector, with a product portfolio that includes prescription medications designed to address unmet medical needs in pain management and neurological conditions. Assertio aims to enhance patient outcomes through its proprietary formulations and targeted therapies.

How the Company Makes Money

Assertio Therapeutics generates revenue primarily through the sale of its pharmaceutical products. The company markets its approved medications through various channels, including wholesalers, pharmacies, and healthcare providers. Key revenue streams include sales from its flagship products as well as royalties and licensing fees from collaborations with other pharmaceutical companies. Additionally, Assertio may engage in partnerships or collaborations that provide upfront payments and milestone payments tied to the achievement of specific development or commercial objectives, further contributing to its earnings.

Assertio Therapeutics Financial Statement Overview

Summary

Assertio Therapeutics is experiencing a challenging financial period with mixed results across its financial statements. While revenue growth is positive, profitability remains a significant issue with negative margins. The balance sheet shows moderate leverage, but the company struggles with generating returns on equity. Cash flow management is an area of concern, with declining free cash flow growth. Overall, the company needs to focus on improving profitability and cash flow generation to enhance its financial health.

Income Statement

Assertio Therapeutics has shown a positive revenue growth rate of 17.3% in the TTM, indicating a recovery from previous declines. However, the company struggles with profitability, as evidenced by negative net profit and EBIT margins. The gross profit margin remains strong at 67.9%, but the negative net profit margin of -36.6% highlights ongoing challenges in managing costs and achieving profitability.

Balance Sheet

The company's debt-to-equity ratio of 0.49 in the TTM suggests a moderate level of leverage, which is an improvement from previous years. However, the return on equity remains negative, indicating that the company is not generating sufficient returns on its equity base. The equity ratio is stable, reflecting a balanced capital structure.

Cash Flow

Assertio's cash flow performance is mixed, with a decline in free cash flow growth by 26.2% in the TTM. The operating cash flow to net income ratio is low at 0.14, indicating challenges in converting earnings into cash. However, the free cash flow to net income ratio of 1.0 suggests that the company is maintaining its cash flow relative to its net income.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	137.35M	124.96M	152.07M	156.23M	111.01M	108.08M
Gross Profit	93.62M	85.73M	125.05M	137.49M	95.18M	92.30M
EBITDA	5.95M	5.15M	53.17M	90.17M	38.78M	-16.28M
Net Income	-28.92M	-21.58M	-331.94M	109.63M	-1.28M	-28.14M
Balance Sheet
Total Assets	319.77M	284.73M	286.42M	413.91M	326.55M	303.27M
Cash, Cash Equivalents and Short-Term Investments	93.43M	100.05M	73.44M	64.94M	36.81M	20.79M
Total Debt	39.17M	40.27M	39.68M	66.87M	75.87M	89.60M
Total Liabilities	213.97M	163.65M	148.42M	188.19M	224.13M	247.76M
Stockholders Equity	105.80M	121.08M	138.00M	225.72M	102.41M	55.51M
Cash Flow
Free Cash Flow	13.33M	26.41M	48.98M	78.32M	5.47M	-65.58M
Operating Cash Flow	13.33M	26.41M	49.60M	78.60M	5.52M	-65.57M
Investing Cash Flow	-12.57M	-48.91M	3.10M	-42.67M	-18.52M	512.80M
Financing Cash Flow	-246.00K	-350.00K	-44.20M	-7.79M	29.03M	-468.55M

Assertio Therapeutics Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 0.78
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ASRT, the sentiment is Neutral. The current price of 0.78 is above the 20-day moving average (MA) of 0.76, below the 50-day MA of 0.82, and above the 200-day MA of 0.74, indicating a neutral trend. The MACD of -0.02 indicates Negative momentum. The RSI at 51.53 is Neutral, neither overbought nor oversold. The STOCH value of 66.60 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for ASRT.

Assertio Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
CPIX	51 Neutral	$39.79M	-12.47	-13.08%	―	12.21%	69.91%
ASRT	49 Neutral	$69.79M	-1.60	-24.48%	―	9.21%	58.12%
SCYX	46 Neutral	$26.45M	-1.11	-53.29%	―	-65.77%	38.61%
TLPH	41 Neutral	$59.66M	-3.21	-86.48%	―	-90.04%	44.40%
RMTI	41 Neutral	$36.84M	―	-16.67%	―	-23.60%	-179.33%
COSM	38 Underperform	$20.93M	-0.68	-63.82%	―	―	―

Assertio Therapeutics Corporate Events

Assertio Therapeutics Reports Strong Q3 Earnings Amid Rolvedon Growth

Assertio Therapeutics’ latest earnings call revealed a generally positive sentiment, driven by significant growth in Rolvedon sales and market share, alongside strategic product advancements. The company showcased a strong financial position, although challenges such as declining Indocin sales due to generic competition and temporary cash flow impacts from sales pull-forwards were acknowledged. Additionally, costs related to the decommercialization of Otrexup were noted as impacting the financials.

Assertio Therapeutics Reports Strong Q3 2025 Results

Assertio Therapeutics is a pharmaceutical company that specializes in offering differentiated products in the oncology, neurology, and pain management sectors, aiming to address patients’ needs through comprehensive commercial capabilities. In its third-quarter 2025 earnings report, Assertio Therapeutics highlighted significant financial achievements and strategic advancements, including the consolidation of operations under Assertio Specialty Pharmaceuticals and the promotion of Paul Schwichtenberg to President and COO. The company reported a notable increase in Rolvedon net product sales, which rose to $38.6 million, a significant jump from the previous year’s $15.0 million, driven by both normal demand and strategic purchases by national distributors. Sympazan sales also saw an increase, while Indocin sales experienced a decline due to generic competition. The company’s gross margin slightly decreased to 72%, and SG&A expenses saw a marginal increase. Assertio’s adjusted EBITDA rose to $20.9 million, a substantial improvement from the previous year’s $4.4 million. Looking ahead, Assertio’s management remains optimistic about achieving its full-year 2025 guidance, with net product sales expected to range between $110 to $112 million and adjusted EBITDA between $14 to $16 million, reflecting the impact of strategic sales and integration efforts.

Assertio Therapeutics Promotes Paul Schwichtenberg to President

On November 10, 2025, Assertio Holdings, Inc. announced its financial results for the third quarter of 2025, highlighting a significant increase in Rolvedon net product sales, which rose to $38.6 million from $15.0 million in the prior-year quarter. This growth was attributed to both normal demand and large purchases by national distributors. The company also promoted Paul Schwichtenberg to the role of President and Chief Operating Officer, effective November 3, 2025, as part of its strategic efforts to consolidate operations and enhance commercial strategies. Assertio narrowed its full-year 2025 net product sales guidance range to $110 to $112 million and adjusted EBITDA range to $14 to $16 million, reflecting the impact of the Rolvedon pull-forward.

The most recent analyst rating on (ASRT) stock is a Hold with a $1.00 price target. To see the full list of analyst forecasts on Assertio Therapeutics stock, see the ASRT Stock Forecast page.

Assertio Therapeutics Announces New CEO Appointment

On October 27, 2025, Assertio Holdings announced the departure of CEO Brendan O’Grady and the appointment of Mark Reisenauer as the new CEO. This leadership transition aims to accelerate growth and enhance efficiency as the company enters 2026, with Reisenauer bringing extensive experience in oncology and specialty spaces to drive long-term value for shareholders and patients.

The most recent analyst rating on (ASRT) stock is a Hold with a $1.00 price target. To see the full list of analyst forecasts on Assertio Therapeutics stock, see the ASRT Stock Forecast page.

Assertio Therapeutics Amends ROLVEDON Supply Agreement

On October 7, 2025, Spectrum Pharmaceuticals, a subsidiary of Assertio Holdings, and Hanmi Pharmaceutical amended their supply agreement for ROLVEDON drug substance, establishing long-term pricing with a mid-single digit percentage reduction. The amendment allows for price adjustments based on market volume and cost increases, requiring Spectrum’s consent for manufacturing changes, and mandates an annual forecasted purchase plan without minimum purchase requirements.

The most recent analyst rating on (ASRT) stock is a Hold with a $1.00 price target. To see the full list of analyst forecasts on Assertio Therapeutics stock, see the ASRT Stock Forecast page.

Assertio Therapeutics’ Earnings Call: Mixed Sentiments and Strategic Shifts

Assertio Therapeutics’ recent earnings call presented a mixed sentiment, highlighting both positive developments and challenges. The company reported strong demand for its product Rolvedon and successful legal settlements, which are positive indicators. However, it also faced a decline in net product sales and decided to discontinue the commercialization of Otrexup. Despite these challenges, Assertio’s financial position remains robust, supporting future strategic transactions.